NeurologyLive® Friday 5 — March 13, 2026

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Click the read more buttons for more details and information about each highlight.

1: How Biotechnology and Advocacy Are Shaping the Future of Neuromuscular Care: John F. Crowley

In a recent interview, John F. Crowley, president and chief executive officer of the Biotechnology Innovation Organization, shared insights on his keynote speech delivered at the 2026 MDA Conference, reflecting on the evolving rare disease ecosystem. [WATCH TIME: 3 minutes]

2: How Migraine Trials Can Better Capture Patient-Centered Outcomes: Amaal Starling, MD, FAHS, FAAN

In a recent interview, Amaal Starling, MD, FAHS, FAAN, associate professor of neurology at Mayo Clinic College of Medicine, discussed how migraine trials can evolve to better incorporate patient-centered outcomes that reflect daily function and quality of life. [WATCH TIME: 3 minutes]

3: Mechanism of Action of Factor XI Inhibitors

In this NeurologyLive Peer Exchange episode, Ashkan Shoamanesh, MD, FRCPC, FESO, Gregory W. Albers, MD, James Siegler, MD, and Eva Mistry, MD, explained how factor XIa inhibitors may prevent post‑stroke clots while sparing hemostasis, offering safer anticoagulation ahead of phase 3. [WATCH TIME: 3 minutes]

4: NeuroVoices: Michio Hirano, MD, on Reflecting on Contributions to Neuromuscular Disease Research

In our latest NeuroVoices Q&A, Michio Hirano, MD, professor of neurology at Columbia University Irving Medical Center, highlighted the decades of research collaboration for patients with neuromuscular disease at the 2026 MDA Conference.

5: Rituximab in NMOSD: Managing Cumulative Infection Risk and Long-Term Tolerability

In this NeurologyLive Special Report episode, Shamik Bhattacharyya, MD, and Philippe-Antoine Bilodeau, MD, discussed the real-world safety signals seen with rituximab—particularly serious and recurrent infections—how to think beyond IgG levels alone, and what clinicians can do to better monitor and mitigate infectious risk while balancing relapse prevention. [WATCH TIME: 6 minutes]

Click here to view our latest video interview shorts with neurology experts.